Navigation Links
New Data Demonstrate Longer-Term Safety Profile of Esbriet®
Date:9/26/2011

lung transplantation, so we hope that this new longer-term safety data will reinforce the known safety and importance of Esbriet as the future standard of care for patients living with IPF," said Giacomo Di Nepi, InterMune's Senior Vice President and Managing Director, Europe.  "Germany is the first country in Europe where Esbriet is now available to patients, and we are glad to be able to offer now this new treatment opportunity to patients with mild to moderate IPF."

RECAP Study Results

At Week 72 in RECAP, mean exposure to pirfenidone 2403 mg/d across both studies was 2.9 years (range, 1-4); 114 patients had received Esbriet 2403 mg/d for at least three years.  The favorable safety and tolerability profile observed in CAPACITY and other prior clinical trials was confirmed in RECAP.

In RECAP, treatment-emergent adverse events (TEAE) and common adverse events (AEs) were very similar to those reported in CAPACITY:

  • 98 percent of RECAP patients reported at least one TEAE compared to 99 percent in the treatment arm and 98 percent in the placebo arm of the CAPACITY program.
  • In RECAP, 33 percent of patients had a serious TEAE compared to 33 percent in the treatment arm and 31 percent in the placebo arm during CAPACITY.
  • The incidence of common AEs in RECAP was very similar to that observed in CAPACITY and these AEs were generally mild to moderate in severity.  The type and frequency of adverse events were generally consistent with observations from the Phase 3 clinical trials; no new safety signals or trends were observed.
  • The overall incidence of photosensitivity or rash was lower in RECAP than in CAPACITY (20 percent of patients vs. 44 percent). Rash and photosensitivity reactions were more common among patients newly initiating treatment with pirfenidone compared with those who were continuing treatment (28 percent vs. 12 percent); however, the incidence w
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
2. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
3. Germgard Lighting Demonstrates the Worlds Most Effective Hand Sterilizer to Protect Against Contagion
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent
6. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
7. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
8. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
9. Topaz Pharmaceuticals Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
10. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
11. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 The ... Bottle washer, Filler, Capper, Blow molder, Shrink wrapper), ... (Still, Flavored, Sparkling) & Region - Trends & ... segments the bottled water processing market with analyses ... terms of value. It also identifies the driving ...
(Date:2/26/2015)... 2015 People with psoriasis and their ... participate in research that aims to improve treatments ... psoriasis registry begins recruiting patients in 2015. ... National Psoriasis Foundation and Corrona, LLC, will initially ... new biologic medication by Novartis Pharmaceuticals for moderate-to-severe ...
(Date:2/26/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... Company 35 th Annual Health Care Conference on Wednesday, ... Boston Marriott Copley Place. A live webcast of the presentation ... be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Bottled Water Processing Market Worth $2,106.5 Million by 2019 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 4First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3
(Date:2/27/2015)... GA (PRWEB) February 27, 2015 ... Martin Ventures, is collaborating with the Atlanta-based software ... the adoption of Jvion’s advanced predictive capabilities suite ... analytics company that identifies and prevents financial and ... need for predictions that help prevent patient deterioration ...
(Date:2/27/2015)... February 27, 2015 Aligned Modern ... local neighborhood health centers, officially welcomes Dr. Alaina ... based in Aligned Modern Health’s Lincoln Square, Streeterville, ... from the National University of Health Sciences and ... She has completed post-graduate coursework in functional ...
(Date:2/27/2015)... Connecticut Community for Addiction Recovery (CCAR) recently received an ... Centers (ADRC), for its shared Recovery Oriented Employment Services ... 2014 Commissioner’s Recognition Award by the CT Department of ... ROES achieved the highest rate of employment in its ... and other drug addiction. More than half of ...
(Date:2/27/2015)... GA (PRWEB) February 27, 2015 Leading ... and Consumer Protection, PartnerTech Inc. President, Gary ... Association of Georgia (TAG) for the TechAmerica DC ... leaders on legislation regarding technology along with the opportunity ... manufacturer of technology driven products, evidenced by their current ...
(Date:2/27/2015)... Bird B Gone, the leader in ... now offers an effective and humane combo of ... to this bird problem. Rarely have two new products ... problem. , Sparrow Charmer™ Bird Caller Lures them , ... broadcasting Bird B Gone’s proprietary sparrow call. Field tested ...
Breaking Medicine News(10 mins):Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 3Health News:PartnerTech Joins Technology Association of Georgia for TechAmerica DC Fly-In 2Health News:PartnerTech Joins Technology Association of Georgia for TechAmerica DC Fly-In 3Health News:New Sparrow Charmer & Sparrow Sky Trap Combo Delivers One-Two Punch to Sparrow Problem 2Health News:New Sparrow Charmer & Sparrow Sky Trap Combo Delivers One-Two Punch to Sparrow Problem 3
... International Symposium on GnRH Analogs in Cancer and ... of fertility drugs. Organon scientists have succeeded in ... hybrid subunit, which extends FSH's active life. This ... active life will mean fewer injections for the ...
... has stated that there is a metabolic threshold that ... activity becomes deleterious for lumbar bone mineral density (LBMD) ... a 10-year period, investigated the longitudinal relationship between daily ... women. They assessed LMBD, habitual daily physical activity, total ...
... of all newly-diagnosed lung cancer cases. Smoking inflicts serious damage ... people quit, as it takes time for the tissue to ... damage in the form of loss of a gene that ... of Texas have now shown that a close chemical relative ...
... the University of Rochester, New York suggests that the ... anti-coagulant properties,which until now is being used to treat ... by stroke. Researchers who conducted the study on mice ... secondary damage associated with ischemic stroke by preventing apoptosis, ...
... But it is no term to be happy about, because ... which could affect those individuals whose work or lifestyle demands ... Sitting for a long time without a break could cause ... into the lungs with possible fatal consequences. This condition is ...
... the Harvard School of Public Health now reveals that caregiving ... found that women who care for a disabled or ill ... findings were reported from a long-running Nurses' Health Study, which ... 54,412 women aged between 46 and 71. They found that ...
Cached Medicine News:Health News:New fertility drug development techniques by Organon 2
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... mounts on a standard ring stand rod ... 1/2" ) mounting rod. The 14cm (5 ... the source of fumes. A top connector ... to an aspirator or vacuum source. Tubing, ...
... These corrosion proof polypropylene exhaust hoods are ... of tanks and draw a stream of ... away from the operator. Other sizes and ... lateral, and double-slot are available on special ...
... The Benchtop Fume Hood is an ... installations in which a number of fume ... schools, junior colleges and universities. Features include ... polyethylene with rounded inside corners for easy ...
Medicine Products: